Takashi Nomizo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Nomizo has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Hiroaki Ozasa
Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
62 shared publications - Takahiro Tsuji
Department of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
62 shared publications - Tomoko Funazo
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
62 shared publications - Akihiko Yoshida
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
61 shared publications - Hironori Yoshida
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
61 shared publications - Kazutaka Hosoya
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
61 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clinical significance of inhaled COPD therapy in advanced or recurrent non-small cell lung cancer in the immune checkpoint inhibitor era: a multicenter retrospective cohort study
- 18 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClinical significance of inhaled COPD therapy in advanced or recurrent non-small cell lung cancer in the immune checkpoint inhibitor era: a multicenter retrospective cohort study
- Open Access
- 7 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation
Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8 + T cell depletion abrogates therapeutic benefit, and combination therapy expands T follicular helper-like cells and induces TLS-like structures. These findings manifest increased adaptive immune response of dual checkpoint blockade in NSCLC BrMs.
- 7 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAnti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation
Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8 + T cell depletion abrogates therapeutic benefit, and combination therapy expands T follicular helper-like cells and induces TLS-like structures. These findings manifest increased adaptive immune response of dual checkpoint blockade in NSCLC BrMs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S8 shows the cell growth assay of KTOR27 cells treated with afatinib with TEAD1 knockdown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S8 shows the cell growth assay of KTOR27 cells treated with afatinib with TEAD1 knockdown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S2 shows cell viability assays of KTOR27 cells treated with VT103 or VT104.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S2 shows cell viability assays of KTOR27 cells treated with VT103 or VT104.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S1 shows the cell viability signal with or without the freezing and thawing procedure.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S1 shows the cell viability signal with or without the freezing and thawing procedure.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S9 shows cell viability assays of PC9, HCC827, and H1975 cells treated with VT104.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S9 shows cell viability assays of PC9, HCC827, and H1975 cells treated with VT104.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Table S7 shows patient characteristics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Table S7 shows patient characteristics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Table S3 shows primers used for qRT-PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Table S3 shows primers used for qRT-PCR.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Data S1 shows the list of compound names and relative cell viability rates.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Data S1 shows the list of compound names and relative cell viability rates.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S11 shows immunofluorescent staining of H1975 cells treated with osimertinib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer
Supplementary Figure S11 shows immunofluorescent staining of H1975 cells treated with osimertinib.